Clinical Trial Update: BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 results for a trial evaluating the combination of BAY 43-9006 (sorafenib) with cetuximab in metastatic colorectal cancer; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-08-07